Drug Trial Radar · NCT03217838
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Jul 31, 2017
Primary completion
Mar 25, 2021
Study completion Mar 25, 2021
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II clinical study to determine the maximum tolerated dose (MTD), and schedule, safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2811 monotherapy or with combination agent(s) in relapsed/refractory acute myeloid leukaemia (AML) participants or treatment-naïve AML participants not eligible for intensive induction therapy. In addition, the study will explore the potential clinical activity by assessing anti-tumour activity in participants. The study was terminated early as a result of AstraZeneca's strategic review across the AZD2811 programme. Part A data were collected for initial cohorts; the MTD/recommended Phase 2 dose (RP2D) dose and schedule of AZD2811 monotherapy or with combination agents were not determined. Part B of the study was not initiated
Conditions
- Acute Myeloid Leukaemia
Interventions
AZD2811Drug
AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
AzacitidineDrug
Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
VenetoclaxDrug
Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Day 1 to Day 28 of first cycle
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 through early termination of the study (approximately 42 months)
- Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Grade 4 TEAEsTime frame: Day 1 through early termination of the study (approximately 42 months)
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Denver, Colorado
Research Site
Sarasota, Florida
Research Site
Detroit, Michigan
Research Site
Charlotte, North Carolina
Research Site
Canton, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Milwaukee, Wisconsin
Research Site
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.